|本期目录/Table of Contents|

[1]何杨.免疫联合化疗诱导治疗ⅢB期肺鳞癌二例[J].中华肺部疾病杂志,2023,(01):135-137.[doi:10.3877/cma.j.issn.1674-6902.2023.01.038 ]
点击复制

免疫联合化疗诱导治疗ⅢB期肺鳞癌二例(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年01期
页码:
135-137
栏目:
病例报告
出版日期:
2023-02-20

文章信息/Info

Title:
-
作者:
何杨
241000 芜湖,皖南医学院第一附属医院弋矶山医院肿瘤内科
Author(s):
-
关键词:
肺鳞状细胞癌;  免疫治疗;  化疗;  诱导治疗
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2023.01.038
摘要:
-
Abstract:
-

参考文献/References:

1 Paik PK, Pillai RN, Lathan CS, et al. New treatment options in advanced squamous cell lung cancer[J]. Am Soc Clin Oncol Educ Book, 2019, 39: e198-e206.
2 王洪武, 金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
3 Cheung AH, Tong JH, Chung LY, et al. EGFR mutation exists in squamous cell lung carcinoma[J]. Pathology, 2020, 52(3): 323-328.
4 Wang H, Sun L, Sang Y, et al. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy[J]. Lung Cancer, 2019, 130: 135-142.
5 Evison M, AstraZeneca UK Limited. The current treatment landscape in the UK for stage Ⅲ NSCLC[J]. Br J Cancer, 2020, 123(Suppl 1): 3-9.
6 Curioni-Fontecedro A, Perentes JY, Gelpke H, et al. Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage ⅢB NSCLC: a multicentre phase 2 trial(SAKK 16/08)[J]. Br J Cancer, 2019, 120(10): 968-974.
7 Wolf M. Adjuvant and inductive systemic treatment in non-small cell lung cancer[J]. Chirurg, 2019, 90(12): 982-990.
8 Bryan DS, Donington JS. The role of surgery in management of locally advanced non-small cell lung cancer[J]. Curr Treat Options Oncol, 2019, 20(4): 27.
9 Palmero R, Vilariño N, Navarro-Martín A, et al. Induction treatment in patients with stage Ⅲ non-small cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(1): 539-554.
10 Ren S, Chen J, Xu X, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC(CameL-Sq): A phase 3 trial[J]. J Thorac Oncol, 2022, 17(4): 544-557.
11 Simon GR. Nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update[J]. Clin Lung Cancer, 2014, 15(6): 391-397.
12 Villaruz LC, Cobo M, Syrigos K, et al. A phase Ⅱ study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage Ⅳ squamous non-small cell lung cancer[J]. Lung Cancer, 2019, 136: 52-56.
13 Zajczkowska R, Kocot-Kpska M, Leppert W, et al. Mechanisms of chemotherapy-induced peripheral neuropathy[J]. Int J Mol Sci, 2019, 20(6): 1451.
14 Klein I, Lehmann HC. Pathomechanisms of paclitaxel-induced peripheral neuropathy[J]. Toxics, 2021, 9(10): 229.
15 Tofthagen CS, Cheville AL, Loprinzi CL. The physical consequences of chemotherapy-induced peripheral neuropathy[J]. Curr Oncol Re, 2020, 22(5): 50.
16 Bland KA, Kirkham AA, Bovard J, et al. Effect of exercise on taxane chemotherapy-induced peripheral neuropathy in women with breast cancer: A randomized controlled trial[J]. Clin Breast Cancer, 2019, 19(6): 411-422.
17 Gu J, Lu H, Chen C, et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis[J]. Support Care Cancer, 2021, 29(12): 7461-7469.
18 Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38.
19 Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes[J]. Clin Exp Immunol, 2020, 200(2): 131-140.
20 Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal[J]. Nat Immunol, 2009, 10(11): 1185-1192.
21 Qian C, Guo H, Chen X, et al. Association of PD-1 and PD-L1 genetic polymorphyisms with type 1 diabetes susceptibility[J]. J Diabetes Res, 2018, 2018: 1614683.
22 Akturk HK, Kahramangil D, Sarwal A, et al. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis[J]. Diabet Med, 2019, 36(9): 1075-1081.
23 Byun DJ, Braunstein R, Flynn J, et al. Immune checkpoint inhibitor-associated diabetes: A single-institution experience[J]. Diabetes Care, 2020, 43(12): 3106-3109.
24 Fang W, Yang Y, Ma Y, et al. Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10): 1338-1350.
25 续广娟, 周 琴, 陈 喆. 注射用卡瑞利珠单抗致糖尿病酮症酸中毒合并血小板减少1例[J]. 中国药师, 2021, 24(3): 531-534.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2023-02-20